pediatric acute myeloid leukemia
Conditions
Interventions
Tolerant to chemotherapy group:Gilteritinib
Intolerant to chemotherapy group:Gilteritinib
Refractory or relapse group:Gilteritinib
Sponsors
Beijing Children's Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. Patients enrolled in China Children's Leukemia Group (CCLG)-AML2019 study; 2. Patients who do not remit from induction therapy, or who have persistently positive MRD after treatment, or whose MRD turn negative and then turn positive again or who have morphological relapse; 3. Patients with FLT3-mutated.
Exclusion criteria
Exclusion criteria: 1. Acute Promyelocytic Leukemia; 2. Junior Myelomonocytic Leukemia; 3. AML secondary to Fanconi Anemia; 4. AML secondary to Kostmann Syndrome; 5. AML secondary to Shwachman Syndrome; 6. AML secondary to other Bone Marrow Failure; 7. Patients who fail to receive systematic chemotherapy according to the protocol; 8. Patients who received any anti-tumor treatment within 2 weeks, except for those who received single IT injection or Hydroxycarbamide or low-dose Ara-c for Leukocytosis and have recovered from the adverse drug reactions; 9. Patients complicated with psychiatric disease or any other diseases that could affect their safety and compliance, participation, follow-up or interpretation of results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Remission State of Bone Marrow;Minimal Residual Disease;Side effect of chemotherapy; | — |
Countries
China
Contacts
Public ContactHuyong Zheng
Beijing Children's Hospital, Capital Medical University
Outcome results
None listed